Clinical trial · Observational
Assessment of the Clinic-pathological Correlation of Basal Cell Carcinoma
Assessment of the Clinic-pathological Correlation of Basal Cell Carcinoma: Establishment of a Prospective Observational Cohort and Followed 3 Years
NCT02825511CI-TRIAL-00047660CAC-CBCcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Assessment of the concordance of the initial clinical and histological diagnosis and to explore its prognostic impact in terms of risk of recurrence.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Basal Cell Carcinoma | Basal Cell Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- A cohort of basal cell carcinoma
- description
- A cohort of surgically treated BCC, primitive clinically suspected or previously biopsied on a 4-month period, an expected number of 3 200 cases. The management of the BCC will be consistent with current recommendations. BCC recurrence and those who received prior medical treatment will be excluded.
Primary outcomes (3)
- measure
- Dimension of basal cell carcinoma.
- timeFrame
- Day 1
- measure
- Number of clinical type of basal cell carcinoma (nodular, superficial or sclerodermiform)
- timeFrame
- Day 1
- measure
- Number of histological type of basal cell carcinoma (nodular, superficial, infiltrating or sclerodermiform)
- timeFrame
- Day 1
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Primitive BCC * BCC clinically suspected or previously biopsied * Supports conventional surgical or micrographic techniques. * Patient able to sign a consent after reading the briefing note Exclusion Criteria: * Recurrent CBC * prior medical treatment * BCC assigned to another operator for removal * Genodermatosis underlying (xeroderma pigmentosum - Gorlin syndrome)
References
Publications (0)
Data not yet available
No reference posted for this study.